156 related articles for article (PubMed ID: 2026500)
1. Determination of lesion to normal bone uptake ratios of skeletal radiopharmaceuticals by QARG (quantitative autoradiography).
Ghiron J; Volkert WA; Garlich J; Holmes RA
Int J Rad Appl Instrum B; 1991; 18(2):235-40. PubMed ID: 2026500
[TBL] [Abstract][Full Text] [Related]
2. Technetium-99m complexes of dimethylaminomethylene diphosphonate (DMAD)--II. Biological distributions of 99mTc-DMAD components isolated by anion exchange HPLC.
Holland ME; Bugaj J; Heineman WR; Deutsch E
Int J Rad Appl Instrum B; 1989; 16(3):313-7. PubMed ID: 2497091
[TBL] [Abstract][Full Text] [Related]
3. A comparison between the diagnostic efficacy of 99mTc-MDP, 99mTc-DPD and 99mTc-HDP for the detection of bone metastases.
Pauwels EK; Blom J; Camps JA; Hermans J; Rijke AM
Eur J Nucl Med; 1983; 8(3):118-22. PubMed ID: 6220908
[TBL] [Abstract][Full Text] [Related]
4. Technetium-1,2-dihydroxy-1,2-bis(dihydroxyphosphinyl)ethane (99mTc-DHPE). A promising new skeletal imaging agent.
Archimandritis SC; Tsolis AK
Eur J Nucl Med; 1987; 13(3):134-8. PubMed ID: 3622557
[TBL] [Abstract][Full Text] [Related]
5. Bone uptake studies in rabbits before and after high-dose treatment with 153Sm-EDTMP or 186Re-HEDP.
Brenner W; Kampen WU; Brümmer C; von Forstner C; Zuhayra M; Czech N; Muhle C; Henze E
J Nucl Med; 2003 Feb; 44(2):247-51. PubMed ID: 12571217
[TBL] [Abstract][Full Text] [Related]
6. Bone lesion detection with carrier-added 99mTc-EDTMP in comparison with 99mTc-DPD.
Fueger BJ; Mitterhauser M; Wadsak W; Ofluoglu S; Traub T; Karanikas G; Dudczak R; Pirich C
Nucl Med Commun; 2004 Apr; 25(4):361-5. PubMed ID: 15097810
[TBL] [Abstract][Full Text] [Related]
7. Is (99m)Tc-labelled pamidronate a better agent than (99m)Tc-medronate for bone imaging?
Kumar V; Kumar D; Howman-Giles RB; Little DG
Nucl Med Commun; 2007 Feb; 28(2):101-7. PubMed ID: 17198350
[TBL] [Abstract][Full Text] [Related]
8. A clinical comparison of MDP and DMAD.
Rosenthall L; Stern J; Arzoumanian A
Clin Nucl Med; 1982 Sep; 7(9):403-6. PubMed ID: 6214358
[TBL] [Abstract][Full Text] [Related]
9. Uptake of bone-seekers is solely associated with mineralisation! A study with 99mTc-MDP, 153Sm-EDTMP and 18F-fluoride on osteoblasts.
Toegel S; Hoffmann O; Wadsak W; Ettlinger D; Mien LK; Wiesner K; Nguemo J; Viernstein H; Kletter K; Dudczak R; Mitterhauser M
Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):491-4. PubMed ID: 16416330
[TBL] [Abstract][Full Text] [Related]
10. Technetium-99m MDP vs technetium-99m dicarboxypropane diphosphonate. A clinical comparison in various pathologic conditions.
Godart G; Durez M; Bevilacqua M; Abramovici J; Robience Y
Clin Nucl Med; 1986 Feb; 11(2):92-7. PubMed ID: 3769350
[TBL] [Abstract][Full Text] [Related]
11. New diphosphonate compounds for skeletal imaging: comparison with methylene diphosphonate.
Subramanian G; McAfee JG; Thomas FD; Feld TA; Zapf-Longo C; Palladino E
Radiology; 1983 Dec; 149(3):823-8. PubMed ID: 6316414
[TBL] [Abstract][Full Text] [Related]
12. New bone-seeking agent: animal study of Tc-99m-incadronate.
Shigematsu M; Shomi S; Iwao H; Ochi H
Ann Nucl Med; 2002 Feb; 16(1):55-9. PubMed ID: 11922209
[TBL] [Abstract][Full Text] [Related]
13. Influence of the phosphate balance on the activity distribution of 99mTc-hydroxy-methylene diphosphonate. Experimental studies in the mouse.
Cronhjort M; Sääf M; Sjöberg HE; Schnell PO; Jacobsson H
Acta Radiol; 1998 Jul; 39(4):427-33. PubMed ID: 9685832
[TBL] [Abstract][Full Text] [Related]
14. Radiopharmacokinetic data for 99mTc-ABP--a new radiopharmaceutical for bone scanning: comparison with 99mTc-MDP.
Arteaga de Murphy C; Meléndez-Alafort L; Montoya-Molina CE; Sepúlveda-Méndez J
Nucl Med Biol; 1997 Jan; 24(1):27-33. PubMed ID: 9080472
[TBL] [Abstract][Full Text] [Related]
15. [A phosphine-substituted diphosphonic acid (HMPD) for improved scintigraphic detection of bone lesions].
Steinsträsser A; Schwarz A; Alexander C; Berberich R; Zimmer M
Nuklearmedizin; 1992 Oct; 31(5):164-71. PubMed ID: 1465353
[TBL] [Abstract][Full Text] [Related]
16. 177Lu-EDTMP: a potential therapeutic bone agent.
Ando A; Ando I; Tonami N; Kinuya S; Kazuma K; Kataiwa A; Nakagawa M; Fujita N
Nucl Med Commun; 1998 Jun; 19(6):587-91. PubMed ID: 10234664
[TBL] [Abstract][Full Text] [Related]
17. Role of mineralisation in the uptake of bone-seeking tracers.
Leitha T
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1369. PubMed ID: 16830119
[No Abstract] [Full Text] [Related]
18. Comparison of 99Tcm-labelled MDP and DMAD bone scanning agents in patients with advanced breast cancer.
Coleman RE; Meier CA; Rubens RD; Fogelman I
Nucl Med Commun; 1988 Jul; 9(7):481-5. PubMed ID: 3173907
[TBL] [Abstract][Full Text] [Related]
19. The influence of the charge and of the tin-ligand ratio on bone uptake of technetium 99m labelled osteotropic radiopharmaceuticals.
Gouaillardou D; Conti ML
Int J Rad Appl Instrum A; 1987; 38(2):103-6. PubMed ID: 3032858
[TBL] [Abstract][Full Text] [Related]
20. 99Tcm-DTPMP as a skeletal scintigraphy agent: distribution in rats in comparison with 99Tcm-MDP.
Láznícek M; Láznícková A; Budský F
Nucl Med Commun; 1996 Dec; 17(12):1016-20. PubMed ID: 9004296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
